Rostislav Christov Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of C$8.76, for a total value of C$87,552.00.

Rostislav Christov Raykov also recently made the following trade(s):

• On Friday, December 20th, Rostislav Christov Raykov acquired 25,000 shares of Fennec Pharmaceuticals stock. The stock was acquired at an average cost of C$3.87 per share, for a total transaction of C$96,840.00.
• On Thursday, December 5th, Rostislav Christov Raykov bought 796 shares of Fennec Pharmaceuticals stock. The shares were bought at an average cost of C$8.52 per share, with a total value of C$6,779.05.

Fennec Pharmaceuticals Trading Up 1.0 %

FRX traded up C$0.09 during trading on Wednesday, hitting C$8.76. 299 shares of the stock were exchanged, compared to its average volume of 865. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 8.02. The firm has a 50 day simple moving average of C$7.75 and a 200 day simple moving average of C$7.63. The firm has a market cap of C$239.67 million, a price-to-earnings ratio of 87.60 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a 1 year low of C$5.65 and a 1 year high of C$15.20.

Analysts Set New Price Targets

Separately, Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.